Frequently Asked Questions
ASAP stands for the “AI-driven Structure-enabled Antiviral Platform”, and highlights the central role that artificial intelligence (AI) and machine learning (ML) play, alongside computational chemistry, in accelerating structure-based drug discovery.
You can follow ASAP on twitter at @asap_discovery.
The origin of the ASAP Center is described in this news post.
You can find a detailed overview of planned ASAP activities here.
We plan to post a list of all viral targets, along with all resources we make openly available to aid the global antiviral discovery community, on this website shortly.
If you’re interested in joining or collaborating with the ASAP Consortium, please contact PIs John Chodera (MSKCC)
<firstname.lastname@example.org>, Alpha Lee (PostEra)
<email@example.com>, and Ben Perry (DNDi)
ASAP is currently funded by:
- Numerous discovery programs are funded by the National Institutes of Health grant number 1U19AI171399-01 via the Antiviral Drug Discovery (AViDD) U19 Centers, part of the Antiviral Program for Pandemics
- The SARS-CoV-2 Mpro preclinical program directed by the Drugs for Neglected Diseases Initiative is funded by the Wellcome Trust via the World Health Organization (WHO) Access to COVID Tools Accelerator (ACT-A) grant 224021/Z/21/Z